Hepatitis
MONDO:0002251An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders.
Also known as: Hepatitis, hepatitis, inflammation of liver, liver inflammation, acute and subacute liver necrosis, acute hepatitis, acute/subac. necrosis of liver, animal hepatitis
734 clinical trials for this condition and its sub-types, 51 tagged with Hepatitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hepatitis
-
Viral hepatitis 12 trials · 443 incl. sub-types
6 sub-types
- Hepatitis B virus infection 251 trials · 274 incl. sub-types Sub-types →
- Hepatitis C virus infection 158 trials · 162 incl. sub-types Sub-types →
- Hepatitis D virus infection 47 trials
- Hepatitis A virus infection 10 trials
- Hepatitis E virus infection 5 trials
- Epstein-Barr virus hepatitis 0 trials
-
Alcoholic hepatitis 32 trials
-
Autoimmune hepatitis 30 trials · 31 incl. sub-types
7 sub-types
- Autoimmune cholangitis 1 trial
- Autoimmune hepatitis type 1 0 trials
- Autoimmune hepatitis type 2 0 trials
- Autoimmune hepatitis type 3 0 trials
- Giant cell hepatitis with autoimmune hemolytic anemia 0 trials
- Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome 0 trials
- Seronegative autoimmune hepatitis 0 trials
-
Drug-induced hepatitis 3 trials
-
Fulminant viral hepatitis 3 trials
-
Granulomatous hepatitis 0 trials
-
Hepatic tuberculosis 0 trials
-
Idiopathic peliosis hepatis 0 trials
Most studied deeper sub-types
-
Booster shot hope: extra hepatitis a vaccine studied for thai kids
Vaccine OngoingThis study looks at whether a second, inactivated hepatitis A vaccine can safely boost protection in healthy Thai children and teens who did not develop enough antibodies after a single dose of a live-attenuated hepatitis A vaccine. About 36 participants who took part in an earli…
Phase 3 • Sponsor: Chiang Mai University • Aim: Vaccine
Last updated Jun 27, 2026 12:37 UTC
-
Can a chat app help liver disease patients cut back on drinking?
Disease control OngoingResearchers are testing whether personalized counseling delivered through a mobile chat app can help people with chronic liver disease reduce their alcohol use. The trial enrolls adults with liver disease who drink at risky levels, and compares chat-based support plus brief advic…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Sep 21, 2026 22:00 UTC
-
DNA vaccine trial aims to train immune system against hepatitis c
Disease control OngoingThis early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo aims to tackle stubborn hepatitis d
Disease control OngoingThis Phase 3 trial tests whether a combination of two drugs, tobevibart and elebsiran, can suppress hepatitis D virus in adults who are still infected despite taking bulevirtide. About 150 participants will receive the combo as injections. The main goal is to see if the virus bec…
Phase 3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to tame rare liver virus
Disease control OngoingThis phase 2 trial tests two experimental drugs, Elebsiran and Tobevibart, in 95 adults with chronic hepatitis D, a serious liver infection. Participants receive the drugs as injections along with a standard oral antiviral. The goal is to see if the combination can lower virus le…
Phase 2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for transplant patients with hepatitis b: safer drug switch under study
Disease control OngoingThis study looks at switching kidney or liver transplant patients with chronic hepatitis B to a drug called tenofovir alafenamide (TAF). The goal is to see if TAF is safer for the kidneys, controls the virus well, and is easier for patients to stick with. The study involves 52 ad…
Phase 4 • Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug duo aims to control hard-to-treat hepatitis delta
Disease control OngoingThis phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the …
Phase 3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug duo takes on rare liver virus in head-to-head trial
Disease control OngoingThis study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D, a serious liver infection. About 100 adults with stable liver disease will receive either the combo…
Phase 2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New imaging study aims to spot liver trouble in obese kids without needles
Diagnosis By invitation onlyThis study follows 300 children aged 9 to 14 with obesity to see if ultrasound and MRI can detect early signs of liver disease. Researchers will compare imaging markers like liver fat and stiffness with standard tests. The goal is to improve diagnosis and monitoring without invas…
Sponsor: Sahlgrenska University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
One shot enough? thai kids' hepatitis a immunity tested years later
Knowledge-focused OngoingThis study follows 60 healthy Thai children and teens who received a single dose of a live-attenuated hepatitis A vaccine about a year ago. Researchers want to see how many still have protective antibodies and at what levels. The goal is to understand long-term immunity and help …
Sponsor: Chiang Mai University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
120,000-Person study hopes to crack the code of chronic illness
Knowledge-focused PausedThis observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC